Interleukin-12 (IL-12) is an inflammatory Th1-driving cytokine that has been clinically used as immune therapy and vaccine adjuvant. Recently, it was reported that patients receiving IL-12 presented hyperalgesia. In the present study, we investigated the mechanical hyperalgesic effect of IL-12 in rats using two tests: 1) paw constant pressure and 2) electronic pressuremeter. In both tests, intraplantar administration of IL-12 (3-30 ng paw Ϫ1 ) caused a dose-and time-dependent mechanical hyperalgesia, which peaked between 3 to 5 h, remaining significantly different from control levels until 7 h and resolved 24 h postinjection. However, the same doses of IL-12 did not induce thermal hyperalgesia, determined using the Hargreaves test. Pretreatments with effective doses of indomethacin (2.5 mg kg Ϫ1 ), atenolol (1 mg kg dimethylpiperidinocarbonyl-L-␥-methylleucyl-D-1-methoxycarboyl-D-norleucine (BQ788) (ET B receptor antagonist; 3-30 nmol paw Ϫ1 ) did inhibit IL-12 hyperalgesia. Furthermore, neither pretreatment with effective doses of antiserum against rat-TNF-␣ (50 l paw Ϫ1 ) nor against IL-18 (10 g paw Ϫ1 ) inhibited the IL-12-induced hyperalgesia. Likewise, antiserum against IL-12 (10 ng paw Ϫ1 ) did not alter IL-18-induced hyperalgesia. In conclusion, we demonstrated for the first time that IL-12 is a prohyperalgesic cytokine that induces mechanical hyperalgesia mediated by endothelin action on the ET B receptor. Therefore, endothelin receptor antagonism could be beneficial in controlling IL-12 therapy-induced pain or hyperalgesia.